Next generation approaches for tumor vaccination

Chinese Clinical Oncology

Volumn 6, Issue 2, 2017, Pages 1-12

  Patel, Anand ^a   Kaufman, Howard L ^a   Disis, Mary L ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antigen; Cancer; Neoantigen; Oncolytic virus; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL VACCINE; BACTERIAL VECTOR; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA VACCINE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; H 101; IMMUNOLOGICAL ADJUVANT; IPILIMUMAB; MOLECULAR THERAPY AGENT; NEOANTIGEN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC COXSACKIEVIRUS A; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PEPTIDE VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; T CELL CHECKPOINT INHIBITOR; TALIMOGENE LAHERPAREPVEC; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YEAST VECTOR; CANCER VACCINE; TUMOR MARKER;

ADOPTIVE CELL TRANSFER THERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL; CANCER GENETICS; CANCER GENOMIC PROFILING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CLINICAL TRIAL (TOPIC); COLON ADENOCARCINOMA; CYTOKINE PRODUCTION; DRUG DEVELOPMENT; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE MUTATION; GENOME ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMUNE RESPONSE; INFUSION RELATED REACTION; INGUINAL PAIN; INJECTION SITE REACTION; LISTERIA MONOCYTOGENES; LYMPHOCYTOPENIA; MELANOMA; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; PAIN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECTUM CARCINOMA; SALMONELLA; SHIGELLA; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; VACCINATION;

EID: 85018939221     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.21037/cco.2017.02.04     Document Type: Article

References (46)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
4. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
5. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80.
6. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39:1-10.
7. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
8. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
9. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
10. Gillanders WE, Mardis E, Fleming T, et al. Safety and immunogenicity of a personalized polyepitope DNA vaccine strategy in breast cancer patients with persistent triple-negative disease following neoadjuvant chemotherapy. ClinicalTrials.gov 2015:NCT02348320. Available online: Https://clinicaltrials.gov/ct2/show/NCT02348320
11. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14:642-62.
12. Kaufman HL, Bines SD. OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010;6:941-9.
13. Xia ZJ, Chang JH, Zhang L, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004;23:1666-70. Chinese.
14. Shafren DR, Dorahy DJ, Ingham RA, et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997;71:4736-43.
15. Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004;10:53-60.
16. Andtbacka RH, Curtie BD, Kaufman H, et al. Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. J Clin Oncol 2015;33:abstr 9030.
17. Shahabi V, Maciag PC, Rivera S, et al. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs 2010;1:235-43.
18. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009;27:3975-83.
19. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015;33:1325-33.
20. Bilusic M, Heery CR, Arlen PM, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014;63:225-34.
21. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
22. A.
23. Curti B. Study of intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in patients with advanced melanoma. ClinicalTrials.gov 2015NCT02307149. Available online: Https://clinicaltrials.gov/ct2/show/NCT02307149
24. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
25. Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017-23.
26. Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program 2014;2014:559-64.
27. Zeng J, Harris TJ, Lim M, et al. Immune modulation and stereotactic radiation: Improving local and abscopal responses. Biomed Res Int 2013;2013:658126.
28. Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007;83:819-25.
29. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012;84:879-80.
30. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
31. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: A double-edged sword. Cancer Cell 2007;12:300-1.
32. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343-9.
33. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-88.
34. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
35. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-35.
36. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
37. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Res 2012;72:3439-44.
38. Lutz ER, Wu AA, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2:616-31.
39. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-8.
40. Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 2016;44:343-54.
41. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-94.
42. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73.
43. Kane MA. Global implementation of human papillomavirus (HPV) vaccine: Lessons from hepatitis B vaccine. Gynecol Oncol 2010;117:S32-5.
44. DuPage M, Jacks T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol 2013;25:192-9.
45. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.
46. Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013;6:18-26.